Immediate access to the recorded webinar
Purification processes constitute more than half of the development costs for a biosimilar. We present an alternative workflow using IEX and mixed mode resins as a viable and cost effective alternative to traditional methods for biosimilar purification.
The global biosimilars market is expected to reach US $10.9B by 2021. Although biosimilars are expected to be significantly cheaper than biologics due to their shorter development times and lower production costs, a further reduction in development costs is required for broader affordability. Purification processes constitute more than half of the development costs, particularly with the use of Protein A based media. Using an IEX workflow along with a mixed mode polish step is a viable and cost effective alternative to traditional methods for biosimilar purification.
Randy Drevland, PhD,
Senior Applications Scientist
Randy Drevland earned his PhD in biochemistry from The University of Texas at Austin in 2009 where he studied the enzymology of archaeal metabolic pathways. In 2016, he joined Bio-Rad Laboratories as a Senior Applications Scientist where his projects include designing a workflow for the purification of biosimilar drugs using Nuvia S, Nuvia Q, and Nuvia cPrime resins.